Big LawOpioids

U.S. Reaches $1.4B Opioid-Drug Settlement With Reckitt Benckiser

Reckitt Benckiser Group PLC will pay up to $1.4 billion to settle U.S. investigations into whether its former pharmaceuticals unit organized a multibillion-dollar fraud to drive up sales of an opioid-addiction treatment.

The U.K. consumer-goods company—which owns Lysol cleaner and Durex condoms—said it struck a deal with the U.S. Department of Justice and the Federal Trade Commission to resolve their long-running investigations into the sales and marketing of Suboxone Film.

In April, the U.S. Department of Justice indicted Indivior for its marketing practices of the opioid addiction treatment. The DOJ said Indivior made billions of dollars by “deceiving health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible and less abusable than other opioid-addiction treatment drugs.” Indivior, the charges allege, was able to encourage prescribers to prescribe the treatment “at high rates and in a clinically unwarranted manner.” 


    Leave a Review or Comment

    Your email address will not be published. Required fields are marked *

    Back to top button